"The Inflation Reduction Act amends the non-interference clause by adding an exception that requires the Secretary of HHS to negotiate prices with drug companies for a small number of single-source brand-name drugs or biologics without generic or biosimilar competitors that are covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). Under the new Drug Price Negotiation Program, the number of drugs selected for price negotiation is 10 Part D drugs for 2026, another 15 Part D drugs for 2027, another 15 Part D and Part B drugs for 2028, and another 20 Part D and Part B drugs for 2029 and later years. These drugs will be selected from the 50 drugs with the highest total Medicare Part D spending and the 50 drugs with the highest total Medicare Part B spending. The number of drugs with negotiated prices available will accumulate over time."
What sort of shell game has she added to gaslighting?
Overall, the interview was poor, didn't reflect well on her. Tim Walz looked sort of silly sitting there like a Secret Service watchman in Butler, PA. Harris was evasive, and seemed to be looking down at her notes. She looked tired and exhauted, but then last week was her big event, so perhaps she was tired. It was billed as an "hour event," but it was more like a half hour, and Harris said little.
No comments:
Post a Comment